StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Northwest Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$50.33M. For fiscal 2025 it was -$59.91M. The highest annual figure on record is -$15.35M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.91M–
FY2024Dec 31, 2024-$66.51M–
FY2023Dec 31, 2023-$55.51M–
FY2022Dec 31, 2022-$67.18M–
FY2021Dec 31, 2021-$52.70M–
FY2020Dec 31, 2020-$86.61M–
FY2019Dec 31, 2019-$27.98M–
FY2018Dec 31, 2018-$41.48M–
FY2017Dec 31, 2017-$54.68M–
FY2016Dec 31, 2016-$79.27M–
FY2015Dec 31, 2015-$126.28M–
FY2014Dec 31, 2014-$101.14M–
FY2013Dec 31, 2013-$55.47M–
FY2012Dec 31, 2012-$43.83M–
FY2011Dec 31, 2011-$26.79M–
FY2010Dec 31, 2010-$15.35M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.61M–
Q1 FY2026Mar 31, 2026-$10.90M–
Q4 FY2025Dec 31, 2025-$13.50M–
Q3 FY2025Sep 30, 2025-$14.32M–
Q2 FY2025Jun 30, 2025-$14.78M–
Q1 FY2025Mar 31, 2025-$17.31M–
Q4 FY2024Dec 31, 2024-$18.50M–
Q3 FY2024Sep 30, 2024-$14.80M–
Q2 FY2024Jun 30, 2024-$17.46M–
Q1 FY2024Mar 31, 2024-$15.74M–
Q4 FY2023Dec 31, 2023-$15.14M–
Q3 FY2023Sep 30, 2023-$13.83M–
Q2 FY2023Jun 30, 2023-$13.58M–
Q1 FY2023Mar 31, 2023-$12.96M–
Q4 FY2022Dec 31, 2022-$18.18M–
Q3 FY2022Sep 30, 2022-$15.62M–
Q2 FY2022Jun 30, 2022-$21.10M–
Q1 FY2022Mar 31, 2022-$12.29M–
Q4 FY2021Dec 31, 2021-$10.68M–
Q3 FY2021Sep 30, 2021-$10.05M–
Q4 FY2020Dec 31, 2020-$23.36M–
Q3 FY2020Sep 30, 2020-$47.88M–
Q2 FY2020Jun 30, 2020-$7.54M–
Q1 FY2020Mar 31, 2020-$7.83M–
Q4 FY2019Dec 31, 2019-$6.73M–
Q3 FY2019Sep 30, 2019-$6.59M–
Q2 FY2019Jun 30, 2019-$6.64M–
Q1 FY2019Mar 31, 2019-$7.77M–
Q4 FY2018Dec 31, 2018-$2.99M–
Q3 FY2018Sep 30, 2018-$9.32M–
Q2 FY2018Jun 30, 2018-$20.35M–
Q1 FY2018Mar 31, 2018-$8.82M–
Q4 FY2017Dec 31, 2017-$17.98M–
Q4 FY2016Dec 31, 2016-$21.25M–
Q3 FY2016Sep 30, 2016-$25.52M–
Q2 FY2016Jun 30, 2016-$15.02M–
Q1 FY2016Mar 31, 2016-$17.48M–
Q4 FY2015Dec 31, 2015-$51.39M–

More Northwest Biotherapeutics figures

See a number that looks wrong?